Get complete Patent Opposition Report for Janssen Biotech

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Your Report Now

Latest oppositions filed by Janssen Biotech

Explore patent oppositions filed by Janssen Biotech against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Patent NumberTitleApplicantOpposition Date
EP3177645Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLINDHOFERMar 16, 2021
EP2780374Binding Molecules For Bcma And Cd3AMGENApr 14, 2020
EP2780375Binding Molecules For Bcma And Cd3AMGENApr 14, 2020
EP2647707Cytotoxicity-Inducing Therapeutic AgentCHUGAI SEIYAKU KABUSHIKI KAISHAMay 24, 2019
EP1810026B7-H1 And Methods Of Diagnosis, Prognosis, And Treatment Of CancerMAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHJan 18, 2019
EP3209309Compositions Comprising Bacterial StrainsCJ BIOSCIENCEDec 14, 2018

Explore Janssen Biotech's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Patent NumberGrant DateTitleTotal Oppositions
EP3883606Nov 20, 2024Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody5
EP2970980Jul 27, 2022Manufacturing Methods To Control C-Terminal Lysine, Galactose And Sialic Acid Content In Recombinant Proteins1
EP3827845Mar 30, 2022Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses5
EP3370770Jan 20, 2021Subcutaneous Formulations Of Anti-Cd38 Antibodies And Their Uses3
EP2938724Oct 28, 2020Culturing Of Human Embryonic Stem Cells At The Air-Liquid Interface For Differentiation Into Pancreatic Endocrine Cells1
EP3219328Jun 17, 2020Human Anti-Il-23 Antibodies, Compositions, Method And Uses2
EP2569419Mar 20, 2019Differentiation Of Human Embryonic Stem Cells1